# Concentra Group Holdings Parent share price today (Concentra Group Holdings Parent, Inc., CON)

> Concentra Group Holdings Parent, Inc.'s share price has risen faster than its earnings: +101.6% in a year, against −12.1% for earnings per share. CON · Healthcare · Medical Care Facilities · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/con

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: $40.15 (+101.6% in a year)
- P/E: 26.3× (higher than 100% of the last 2.3 years)
- Revenue (Jun 2026): $606 M (+10.0% on a year ago)
- Profit (Jun 2026): $63.9 M (+45.2% on a year ago)
- Operating margin: 19.3% (+2.3 points on a year ago)
- ROE: 39%, FY25
- ROIC: 11.7%, against a 6.6% cost of capital: +5.1 points

The main question: the share price moved +101.6% in a year while yearly earnings per share moved −12.1%. The difference came from the market paying a higher multiple. ## What is the Concentra Group Holdings Parent share price today? Concentra Group Holdings Parent, Inc.'s share price was $40.15 at the close on 3 November 2026. It has been rising for 24 weeks. That is 40.0% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 23 weeks in a row. In the last 52 weeks it traded between $19 and $40, and at that close it sat 99% of the way up from that low. Over the last 2.3 years the share price moved +76% while the S&P 500 moved +39%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Concentra Group Holdings Parent pay? Concentra Group Holdings Parent, Inc. paid $0.25 per share over the last four reported quarters. The most recent declaration was $0.06 for Jun 2026. At today's price of $40.15 that is a yield of 0.62%, based on dividends already paid, not a forecast. ## Which stock lists is Concentra Group Holdings Parent on? Concentra Group Holdings Parent is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Concentra Group Holdings Parent profitable? Concentra Group Holdings Parent, Inc. earned $63.9 M of net profit in the Jun 2026 quarter, +45.2% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY25 profit was $164 M. Over 4 years profit has grown −5.4% a year on average. That is 10.5% of the quarter's revenue. The same quarter a year earlier earned $44.0 M. For the full year, FY25 profit was $164 M (−1.3% on the year before). Why profit moved: revenue changed +10.0% on a year earlier and the margin moved +2.3 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +35.2% and revenue +14.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Concentra Group Holdings Parent make, and is it growing? Concentra Group Holdings Parent, Inc. reported $606 M of revenue in the Jun 2026 quarter, +10.0% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 4 years it has grown 5.7% a year on average. The last full year, FY25, came in at $2.2 B. The last four reported quarters add to $2.3 B. FY25 revenue was $2.2 B, +13.9% on the year before. Recent pace: the last four quarters grew +14.1% on average, against 5.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +14.0%, against +10.9% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +31.7%, against +3.6% a year (accelerating). ## How much of every $100 of sales does Concentra Group Holdings Parent keep? Concentra Group Holdings Parent, Inc.'s operating margin was 19.3% in the Jun 2026 quarter, 2.3 percentage points higher than the same quarter a year ago. Across 5 years it has been between 15.0% and 21.9%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.3 percentage points on the year while gross margin changed +2.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Concentra Group Holdings Parent's profit turning into cash? Over the last 3 years, 155% of Concentra Group Holdings Parent, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $279 M of operating cash against $164 M of profit. After $82.3 M of spending on assets, $197 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Concentra Group Holdings Parent's cash go? Concentra Group Holdings Parent, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $212 M on assets over the last 3 years. Averaged over those years that is 3.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $212 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Concentra Group Holdings Parent's P/E ratio, and how does it compare with its own history? Concentra Group Holdings Parent, Inc.'s P/E is 26.3×, about the highest it has ever been. Its usual P/E (the middle reading) is 16.5×, over 2.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −12.1% while the price moved +101.6%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Concentra Group Holdings Parent business getting better or worse? Concentra Group Holdings Parent, Inc.'s business is turning around. Profit growth has swung from −21.4% at its low to +45.2%, rising from a low 5 quarters ago (from single-quarter figures), with ROCE steady at 14.8%. This is based on 11 quarters of 3 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Concentra Group Holdings Parent earn on its capital? Concentra Group Holdings Parent, Inc. earned a ROE of 39% in FY25. That is up from a low of 15% in FY23. Its return on capital used (ROIC) is 5.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.6% net margin and 0.76× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 7.6% net margin × 0.76× asset turnover × 6.80× leverage (assets divided by equity) ≈ 39.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 11.7% − 6.6% = +5.1 percentage points. The 6.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Concentra Group Holdings Parent have too much debt? Concentra Group Holdings Parent, Inc. has total debt of $2.1 B against shareholder equity of $506 M as of Jun 2026, so its debt is 4.23× its equity. Year by year, that ratio went from 1.04 in FY22 to 5.01 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Concentra Group Holdings Parent shareholding pattern? 3.1% of Concentra Group Holdings Parent, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Concentra Group Holdings Parent from balance-sheet trouble? For Concentra Group Holdings Parent, Inc., the Z-score is 2.03. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.03 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Concentra Group Holdings Parent rank in its industry? 71.3 out of 100, rank 1 of 30 in Medical Care Facilities, with 81% of the evidence available. Concentra Group Holdings Parent, Inc. scores 71.3 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 24.4 + 16.6 + 13 + 17.3 = 71.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Concentra Group Holdings Parent compared with? Concentra Group Holdings Parent ranks 1 of 30 Medical Care Facilities companies on the 4-Factor Sector Score, with 71.3 out of 100. 1. Concentra Group Holdings Parent, Inc. this page CON · leader · Most evidence points up · 81% evidence 71.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 14% · Profit 32.6% · Operating margin change 2.3 points · 83% evidence Capital efficiency 16.6/25 · ROCE 14.5% · Operating margin 19.3% · 76% evidence Valuation 13.0/20 · P/E 19.5× · PEG 0.65 · 65% evidence Relative strength 17.3/20 · Lead over its industry 18.3% · Lead over S&P 500 41.8% · 1 year 107.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.4 + 16.6 + 13 + 17.3 = 71.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Tenet Healthcare Corporation](https://www.sectoralpha.in/us/stocks/thc) THC · losing its lead · Evidence leans up · 81% evidence 64.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 5.4% · Profit 32.4% · Operating margin change 2.1 points · 83% evidence Capital efficiency 17.1/25 · ROCE 15% · Operating margin 18.2% · 76% evidence Valuation 15.3/20 · P/E 7.2× · PEG 0.35 · 65% evidence Relative strength 11.1/20 · Lead over its industry -3.8% · Lead over S&P 500 16.9% · 1 year 29.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21 + 17.1 + 15.3 + 11.1 = 64.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [AMN Healthcare Services, Inc.](https://www.sectoralpha.in/us/stocks/amn) AMN · breaking out · Evidence leans up · 64% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 23.9% · Profit n/a · Operating margin change 3.4 points · 62% evidence Capital efficiency 9.1/25 · ROCE 10.1% · Operating margin 4% · 76% evidence Valuation 10.4/20 · P/E 12× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.8% · Lead over S&P 500 63.5% · 1 year 153.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.3 + 9.1 + 10.4 + 19.6 = 64.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Pediatrix Medical Group, Inc.](https://www.sectoralpha.in/us/stocks/md) MD · turning · Evidence leans up · 81% evidence 62.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 0.6% · Profit 61.5% · Operating margin change -0.2 points · 83% evidence Capital efficiency 14.6/25 · ROCE 14.8% · Operating margin 13.4% · 76% evidence Valuation 13.1/20 · P/E 11.6× · PEG 0.8 · 65% evidence Relative strength 15.2/20 · Lead over its industry 1.2% · Lead over S&P 500 23% · 1 year 39.5% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.4 + 14.6 + 13.1 + 15.2 = 62.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Healthcare Services Group, Inc.](https://www.sectoralpha.in/us/stocks/hcsg) HCSG · turning · Evidence leans up · 85% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 4% · Profit 100% · Operating margin change -3.2 points · 95% evidence Capital efficiency 14.5/25 · ROCE 17.7% · Operating margin 6.7% · 76% evidence Valuation 14.4/20 · P/E 13.4× · PEG 0.43 · 65% evidence Relative strength 12.6/20 · Lead over its industry -4.8% · Lead over S&P 500 15.9% · 1 year 48.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 14.4 + 12.6 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Encompass Health Corporation](https://www.sectoralpha.in/us/stocks/ehc) EHC · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.5% · Profit 20.2% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.1/25 · ROCE 17% · Operating margin 18.1% · 76% evidence Valuation 12.4/20 · P/E 16.2× · PEG 0.8 · 65% evidence Relative strength 12.9/20 · Lead over its industry -4.8% · Lead over S&P 500 16.2% · 1 year 16.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 18.1 + 12.4 + 12.9 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Nutex Health Inc.](https://www.sectoralpha.in/us/stocks/nutx) NUTX · leader · Evidence leans up · 64% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 6.8% · Profit 100% · Operating margin change 44 points · 62% evidence Capital efficiency 18.6/25 · ROCE 56.8% · Operating margin 57.8% · 76% evidence Valuation 10.9/20 · P/E 6.5× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -5.5% · Lead over S&P 500 14.2% · 1 year 56.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.5 + 18.6 + 10.9 + 8.3 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aveanna Healthcare Holdings Inc.](https://www.sectoralpha.in/us/stocks/avah) AVAH · leader · Too little evidence to rank firmly · 58% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.3/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 45% evidence Capital efficiency 15.3/25 · ROCE 17.7% · Operating margin 12.6% · 76% evidence Valuation 10.7/20 · P/E 7.2× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 14.4% · Lead over S&P 500 37.9% · 1 year 51.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 15.3 + 15.3 + 10.7 + 18.2 = 59.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Addus HomeCare Corporation](https://www.sectoralpha.in/us/stocks/adus) ADUS · turning · Evidence leans up · 81% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 15.9% · Profit 27.7% · Operating margin change 0.3 points · 83% evidence Capital efficiency 12.9/25 · ROCE 11.4% · Operating margin 9.7% · 76% evidence Valuation 13.0/20 · P/E 17.4× · PEG 0.67 · 65% evidence Relative strength 10.7/20 · Lead over its industry -8.5% · Lead over S&P 500 11.9% · 1 year 11.9% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21 + 12.9 + 13 + 10.7 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [HCA Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/hca) HCA · breaking out · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 7.3% · Profit 14.6% · Operating margin change -0.7 points · 83% evidence Capital efficiency 19.9/25 · ROCE 26.3% · Operating margin 15.2% · 76% evidence Valuation 14.3/20 · P/E 12.6× · PEG 0.49 · 65% evidence Relative strength 7.2/20 · Lead over its industry -21.2% · Lead over S&P 500 -2.7% · 1 year -2.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 19.9 + 14.3 + 7.2 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) UHS · losing its lead · Evidence leans up · 81% evidence 56.3 out of 100 Growth Capital Valuation Relative
12. [LifeStance Health Group, Inc.](https://www.sectoralpha.in/us/stocks/lfst) LFST · turning · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative
13. [National HealthCare Corporation](https://www.sectoralpha.in/us/stocks/nhc) NHC · quiet · Evidence leans up · 81% evidence 54.0 out of 100 Growth Capital Valuation Relative
14. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) PACS · quiet · Evidence leans up · 71% evidence 53.7 out of 100 Growth Capital Valuation Relative
15. [Fresenius Medical Care AG](https://www.sectoralpha.in/us/stocks/fms) FMS · basing · Evidence leans up · 81% evidence 50.7 out of 100 Growth Capital Valuation Relative
16. [Chemed Corporation](https://www.sectoralpha.in/us/stocks/che) CHE · quiet · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative
17. [Guardian Pharmacy Services, Inc.](https://www.sectoralpha.in/us/stocks/grdn) GRDN · quiet · Evidence leans down · 64% evidence 49.3 out of 100 Growth Capital Valuation Relative
18. [Surgery Partners, Inc.](https://www.sectoralpha.in/us/stocks/sgry) SGRY · turning · Evidence leans down · 64% evidence 48.8 out of 100 Growth Capital Valuation Relative
19. [DaVita Inc.](https://www.sectoralpha.in/us/stocks/dva) DVA · turning · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
20. [Astrana Health, Inc.](https://www.sectoralpha.in/us/stocks/asth) ASTH · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
21. [The Pennant Group, Inc.](https://www.sectoralpha.in/us/stocks/pntg) PNTG · turning · Evidence leans down · 81% evidence 43.9 out of 100 Growth Capital Valuation Relative
22. [The Ensign Group, Inc.](https://www.sectoralpha.in/us/stocks/ensg) ENSG · turning · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
23. [agilon health, inc.](https://www.sectoralpha.in/us/stocks/agl) AGL · quiet · Evidence leans down · 64% evidence 41.2 out of 100 Growth Capital Valuation Relative
24. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) OPCH · breaking out · Evidence leans down · 81% evidence 41.0 out of 100 Growth Capital Valuation Relative
25. [Acadia Healthcare Company, Inc.](https://www.sectoralpha.in/us/stocks/achc) ACHC · quiet · Evidence leans down · 71% evidence 37.5 out of 100 Growth Capital Valuation Relative
26. [U.S. Physical Therapy, Inc.](https://www.sectoralpha.in/us/stocks/usph) USPH · leader · Evidence leans down · 81% evidence 36.3 out of 100 Growth Capital Valuation Relative
27. [Sonida Senior Living, Inc.](https://www.sectoralpha.in/us/stocks/snda) SNDA · basing · Evidence leans down · 64% evidence 36.2 out of 100 Growth Capital Valuation Relative
28. [Ardent Health, Inc.](https://www.sectoralpha.in/us/stocks/ardt) ARDT · losing its lead · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [Brookdale Senior Living Inc.](https://www.sectoralpha.in/us/stocks/bkd) BKD · quiet · Most evidence points down · 64% evidence 32.8 out of 100 Growth Capital Valuation Relative
30. [Select Medical Holdings Corporation](https://www.sectoralpha.in/us/stocks/sem) SEM · Too little evidence to rank firmly · 36% evidence 50.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Care Facilities](https://www.sectoralpha.in/us/sectors/medical-care-facilities), all 30 compared on one page. ## Which companies are close to Concentra Group Holdings Parent in size? Concentra Group Holdings Parent is the 10th largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Universal Health Services, Inc., PACS Group, Inc. and Chemed Corporation. Just below it: LifeStance Health Group, Inc., Option Care Health, Inc. and National HealthCare Corporation. ### Medical Care Facilities companies close in size

1. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) $10.4 billion
2. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) $7.4 billion
3. [Chemed Corporation](https://www.sectoralpha.in/us/stocks/che) $6.9 billion
4. Concentra Group Holdings Parent, Inc. $5.1 billion
5. [LifeStance Health Group, Inc.](https://www.sectoralpha.in/us/stocks/lfst) $5.1 billion
6. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) $4.8 billion
7. [National HealthCare Corporation](https://www.sectoralpha.in/us/stocks/nhc) $3.2 billion

[All 38 Medical Care Facilities companies, largest first](https://www.sectoralpha.in/us/sectors/medical-care-facilities#all-companies)

### Companies close in size in other industries

1. [West Fraser Timber Co. Ltd.](https://www.sectoralpha.in/us/stocks/wfg) $5.2 billion · Lumber & Wood Production
2. [Trex Company, Inc.](https://www.sectoralpha.in/us/stocks/trex) $5.1 billion · Building Products & Equipment
3. Concentra Group Holdings Parent, Inc. $5.1 billion
4. [Red Rock Resorts, Inc.](https://www.sectoralpha.in/us/stocks/rrr) $5.1 billion · Resorts & Casinos
5. [Axos Financial, Inc.](https://www.sectoralpha.in/us/stocks/ax) $5.1 billion · Banks - Regional

## What else do people ask about Concentra Group Holdings Parent? ### What were Concentra Group Holdings Parent's latest quarterly results? Concentra Group Holdings Parent, Inc. reported revenue of $606 M and net profit of $63.9 M for the Jun 2026 quarter. Revenue rose 10.0% and profit rose 45.2% compared with a year earlier. Earnings per share were $0.51 (as of 3 November 2026). ### What is Concentra Group Holdings Parent's market cap? Concentra Group Holdings Parent, Inc.'s market capitalisation is $5.1 B at a stock price of $40.15. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Concentra Group Holdings Parent performing? Concentra Group Holdings Parent, Inc.'s share price has been rising for 24 weeks. In its latest quarter, revenue rose 10.0% and profit rose 45.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 23 weeks running (as of 3 November 2026). ### Will Concentra Group Holdings Parent's stock price go up? This page does not forecast Concentra Group Holdings Parent, Inc.'s stock price. What it shows instead: the stock price is $40.15, and it has been rising for 24 weeks. Its P/E of 26.3× is higher than 100% of its own last 2 years (as of 3 November 2026). ### Where is Concentra Group Holdings Parent in its business cycle? Concentra Group Holdings Parent, Inc.'s FY25 operating margin was 16.0%, against a 5-year range of 15.0% to 21.9%: the low end of its own range, which is often where recoveries start. The latest quarter was 19.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Concentra Group Holdings Parent story? The main question: the share price moved +101.6% in a year while yearly earnings per share moved −12.1%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Concentra Group Holdings Parent a stock worth studying right now? What the numbers show: Concentra Group Holdings Parent, Inc.'s share price has risen faster than its earnings: +101.6% in a year, against −12.1% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.